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MULTI-OBJECTIVE OPTIMAL DESIGNS IN COMPARATIVE
CLINICAL TRIALS WITH COVARIATES: THE REINFORCED
DOUBLY ADAPTIVE BIASED COIN DESIGN
By Alessandro Baldi Antognini and Maroussa Zagoraiou
University of Bologna
The present paper deals with the problem of allocating patients to
two competing treatments in the presence of covariates or prognostic
factors in order to achieve a good trade-off among ethical concerns,
inferential precision and randomness in the treatment allocations. In
particular we suggest a multipurpose design methodology that com-
bines efficiency and ethical gain when the linear homoscedastic model
with both treatment/covariate interactions and interactions among
covariates is adopted. The ensuing compound optimal allocations of
the treatments depend on the covariates and their distribution on
the population of interest, as well as on the unknown parameters
of the model. Therefore, we introduce the reinforced doubly adap-
tive biased coin design, namely a general class of covariate-adjusted
response-adaptive procedures that includes both continuous and dis-
continuous randomization functions, aimed to target any desired allo-
cation proportion. The properties of this proposal are described both
theoretically and through simulations.
1. Introduction. In the medical profession physicians are expected to act
in the best interests of each patient under their care, but in clinical trials
the patients are statistical units in an experiment, and the demands of in-
dividual care and experimental information often come into conflict. Thus
the ensuing ethical problem is how to balance the welfare of the patients
in the trial against a possible knowledge gain that will improve the care
of future patients. In experimental medicine it is commonly believed that
randomized trials are the answer, especially in the case of Phase III clinical
trials, where the aim is to compare the efficacy of two available treatments
and patients are sequentially randomized to one of them. In this context,
several design methodologies have been recently proposed in order to derive
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suitable target allocations of the treatments that represent a compromise
between ethical demands and inferential goals [4, 17, 22]. These targets de-
pend in general on the unknown model parameters and can be implemented
by adopting suitable response-adaptive procedures, such as the sequential
maximum likelihood design [15], the doubly adaptive biased coin design [13]
and the efficient randomized-adaptive design (ERADE) [14], converging to
them.
An additional peculiarity of Phase III trials is that they usually involve
some set of important prognostic factors or covariates. The role of these
factors may be crucial in order to derive correct inferential conclusions about
the treatment effects and this is one of the reasons for which taking into
account the covariates has now become of primary importance not only
from an inferential point of view but also from a design perspective (for
a recent literature [2, 5, 18, 20]).
In the last decade there has been a growing statistical interest in the topic
of adaptive designs adjusted for covariates and, in particular, in covariate-
adjusted response-adaptive (CARA) randomization methods; see [12, 19,
23]. This is a class of sequential allocation procedures that modifies the prob-
abilities of treatment assignments on the basis of the available information—
that is, earlier responses and allocations, past covariate profiles and the
covariate information of the present patient—with the aim of skewing the
allocations towards the treatment that appears to be superior or, more gen-
erally, of converging to a desired target that should incorporate inferential
demands related to optimal inference about the treatment effects and, even-
tually, ethical concerns.
Even if in the presence of prognostic factors the inferential methods, as
well as the ethical goals, change on the basis of the nature of the responses
and the covariates, the design literature has essentially focused on the simpli-
fied scenario of absence of treatment/covariate interactions; see, for instance,
[3, 7, 8]. In this context, the relative performance of the treatments is the
same for every subject’s profile, so that the ethical demand simply consists
of allocating the best treatment to as many patients as possible, indepen-
dently on their covariates. This also explains the absence of methodological
proposals through which one can derive target allocations that, by incorpo-
rating both inferential and ethical considerations, depend on the covariates.
Whereas, in the more complex scenario of treatment/covariate interactions,
the covariates play a fundamental role also from an ethical viewpoint, since
the superiority/inferiority of a given treatment, as well as the discrepancy
between the treatment effects, depend on the subject’s profiles.
Therefore, one of the primary aims of the present paper consists of analyz-
ing, from a design perspective, the linear model with both treatment/covari-
ate interactions and interactions among covariates, in terms of ethical impact
as well as inferential efficiency. After deriving the analytical expressions of
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the most popular information criteria, we propose a multipurpose design
strategy based on a compound optimization approach, that combines infer-
ential precision and ethical gain by means of flexible weights, which can be
fixed a priori by the experimenter, or they may be functions of the unknown
model parameters.
This multipurpose criterion leads to a locally optimal allocation which
depends, in general, on the covariates and their population distribution, as
well as on the unknown model parameters, and allows to promote for ev-
ery profile a suitable compromise between information and ethical demands.
Furthermore, we introduce the reinforced doubly adaptive biased coin de-
sign (RDBCD), namely a new class of CARA procedures that generalizes
some earlier works [1, 23] and also extends several procedures proposed in
the literature, such as the doubly adaptive biased coin design and the ER-
ADE, to the covariate setting. The RDBCD, which admits both continuous
and discontinuous randomization functions, can target any desired alloca-
tion proportion, allowing also to force closeness to the chosen target in an
appropriate way, while maintaining randomization. We show, both theoret-
ically and through simulations, that the proposed procedure has desirable
properties, asymptotically and, in particular, for small samples.
The paper is structured as follows. Starting from the notation in Section 2,
Sections 3 and 4 deal with the optimal designs for inference and ethics, re-
spectively. Section 5 describes the combined approach, while the properties
of the ensuing optimal compound target are discussed in Section 6. In Sec-
tion 7 we introduce the RDBCD, showing its asymptotic properties as well
as the asymptotic inference related to the adoption of such a procedure.
Section 8 deals with some finite sample comparisons between our proposal
and some of the fundamental procedures proposed in the literature. We end
the paper with a brief discussion in Section 9.
Motivated by the clinical practice, the present paper takes into account
categorical covariates, since in the large majority of real Phase III clinical
trials the prognostic factors are polytomous and, even if quantitative, they
are often categorized by adopting suitable thresholds. Furthermore, for ease
of notation we deal with just two covariates, but the extension to the case
of several factors is straightforward (see [6]).
2. The linear model with covariates. Let A and B be two competing
treatments. We suppose that for each subject entering the trial we observe
a vector Z of concomitant categorical variables. Moreover, we assume the
covariates to be random, that is, they are not under the experimenters’
control when the subjects turn up for the trial, but they can be measured
before assigning a treatment. Then the treatments are assigned according
to a given randomization rule, with δ an indicator variable such that δ = 1
or 0 if the subject is assigned to A or B, respectively, and an outcome Y
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is observed. Conditionally on the covariates and the treatments, patients’
responses are assumed to be independent. A common model for the response
that accounts for treatment/covariate interactions is the following linear
homoscedastic model:
E(Yi) = δiµA + (1− δi)µB + f(zi)t(δiβA + (1− δi)βB),
(2.1)
V (Yi) = σ
2, i= 1, . . . , n,
where Yi is the outcome of the ith subject, µA and µB are the baseline
treatment effects, f(·) is a known vector function, zi is the vector of covari-
ates observed on the ith individual and βA,βB are p-dim vectors of possibly
different regression parameters related to A and B, respectively. Under this
model µA, µB,βA and βB are of interest since the relative performance of
the treatments depends on the patient’s covariates. Indeed, for any given
covariate profile zi, we obtain
θ(zi) =E(Yi | δi = 1,Zi = zi)−E(Yi | δi = 0,Zi = zi)
(2.2)
= µA − µB + f(zi)t(βA −βB) = α+ f(zi)tτ .
After n assignments, let F = (f(z)t)n×p, δn = (δ1, . . . , δn)
t, ∆n = diag(δn)
andX= [δn :1n−δn :∆nF : (In−∆n)F], where 1n and In are the n-dim vec-
tor of ones and the n-dim identity matrix, respectively. Moreover, let γˆn =
(µˆA, µˆB , βˆ
t
A, βˆ
t
B)
t be the least square estimator of γ = (µA, µB,β
t
A,β
t
B)
t,
then if (XtX)−1 exists, the variance–covariance matrix is
V (γˆn) = σ
2(XtX)−1 = n−1σ2M−1,
where M is the (2 + 2p)-dim average (per observation) information matrix
M=
1
n

n∑
i=1
δi 0 δ
t
nF 01×p
0 n−
n∑
i=1
δi 01×p (1n − δn)tF
Ftδn 0p×1 F
t∆nF 0p×p
0p×1 F
t(1n − δn) 0p×p Ft(In −∆n)F

.(2.3)
Remark 2.1. In the absence of treatment/covariate interactions βA =
βB = β, that is, τ = 0, and the homoscedastic model (2.1) becomes
E(Yi) = δiµA + (1− δi)µB + f(zi)tβ, i= 1, . . . , n.(2.4)
In this case, it is customary to regard β as a nuisance parameter, since
from (2.2) θ(zi) = µA − µB for any given covariate profile zi, so that the
inferential interest typically lies in estimating µA and µB , or µA − µB , as
precisely as possible.
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3. Inferential optimality and balanced designs. In order to avoid cum-
bersome notation, from now on we assume, without loss of generality, only
two categorical covariates, that is, Z= (T,W ). Suppose that T is categorized
into levels t0, t1, . . . , tJ and let w0,w1, . . . ,wL be the levels of W , so that T
andW can be represented by a J -dimensional vector T and a L-dimensional
vector W of dummy variables, respectively, where t0 and w0 are the refer-
ence categories. Assume that {Zi, i≥ 1} is a sequence of i.i.d. random vec-
tors, where each Zi is distributed in the population according to Pr{Zi =
(tj ,wl)}= p(j, l)> 0 (j = 0, . . . , J ; l = 0 . . . ,L), where
∑J
j=0
∑L
l=0 p(j, l) = 1.
Moreover, in order to account for the general situation of both treatment/
covariate interactions and interaction among covariates in the rest of the
paper, we let
f t(z) = (Tt,Wt,Tt ⊗Wt),(3.1)
that is, f(·) is the p-dim vector including all interaction effects, with p =
J +L+ J ·L.
At the end of a trial with n assignments, let Nn(j, l) =
∑n
i=1 1{Zi=(tj ,wl)}
be the number of subjects within the stratum (tj ,wl), where 1{·} repre-
sents the indicator function, N˜n(j, l) =
∑n
i=1 δi1{Zi=(tj ,wl)} the number of
allocations to A within this stratum and πn(j, l) the corresponding pro-
portion, that is, πn(j, l) = Nn(j, l)
−1N˜n(j, l), for any j = 0, . . . , J and l =
0, . . . ,L. Moreover, let Nn = {Nn(j, l) : j = 0, . . . , J ; l = 0, . . . ,L} and pin =
{πn(j, l) : j = 0, . . . , J ; l= 0, . . . ,L}.
Adopting model (2.1), the design for optimal inference consists in allo-
cating the treatments so as to minimize one of the following criteria:
C1 detV (γˆn) = det(n
−1σ2M−1);
C2 detV
(βˆA
βˆB
)
= det(n−1σ2DtM−1D), where Dt = (02p×2 : I2p);
C3 trV (γˆn) = tr(n
−1σ2M−1);
C4 trV
(βˆA
βˆB
)
= tr(n−1σ2DtM−1D);
C5 trV (βˆA − βˆB) = tr(n−1σ2EtM−1E),Et = (0p×2 : Ip :−Ip)
with M−1 replaced by the Moore–Penrose inverse, if needed. It is easy to
check that C1–C5 are convex functions of M, invariant with respect to
permutations of the bottom two block rows and the two right-hand block
columns of M.
For given covariates, the jointly balanced design
pi∗I = {π∗I (j, l) = 1/2, for any j = 0, . . . , J and l= 0, . . . ,L},(3.2)
is optimal for model (2.1) with respect to any criterion ΦI of the informa-
tion matrix M, which is convex and invariant w.r.t. permutations of the
bottom two block rows and the two right-hand block columns, as well as the
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first two rows and columns. To see this, it is straightforward to check that
assuming (3.2) the ensuing information matrix
M∗ =
1
2n

n 0 1tnF 01×p
0 n 01×p 1
t
nF
Ft1n 0p×1 F
tF 0p×p
0p×1 F
t1n 0p×p F
tF
(3.3)
is invariant w.r.t. permutations of the bottom two block rows and the two
right-hand block columns, as well as the first two rows and columns. For
any information matrix M of the type (2.3), by the simultaneous permu-
tation of the first two rows and two columns as well as the bottom two
block rows and the two right-hand block columns, we get the informa-
tion matrix M˜ corresponding to the design which switches treatments A
and B. Clearly ΦI(M˜) = ΦI(M), (M + M˜)/2 =M
∗ and then by convex-
ity
ΦI(M
∗) = ΦI(
1
2(M+ M˜))≤ 12 [ΦI(M) +ΦI(M˜)] = ΦI(M).
Note that, independently on the presence or absence of treatment/covariate
interactions, the jointly balanced allocation (3.2) is still optimal, even in
the absence of interactions among covariates; see [5] for a detailed discus-
sion.
Proposition 3.1. Assuming model (2.1) with (3.1), inferential crite-
ria C1–C5 can be simplified as follows:
C1: det
(
σ2
n
M−1
)
=
σ4+4p∏J
j=0
∏L
l=0 πn(j, l)[1− πn(j, l)]Nn(j, l)2
,(3.4)
C2: det
(
σ2
n
DtM−1D
)
=
(
∑n
i=1 δi)(n−
∑n
i=1 δi)σ
4p∏J
j=0
∏L
l=0 πn(j, l)[1− πn(j, l)]Nn(j, l)2
,(3.5)
C3: tr
(
σ2
n
M−1
)
= σ2 ×
[
J∑
j=1
L∑
l=1
1
Nn(j, l)πn(j, l)[1− πn(j, l)]
+
J∑
j=1
L+1
Nn(j,0)πn(j,0)[1− πn(j,0)]
(3.6)
+
L∑
l=1
J + 1
Nn(0, l)πn(0, l)[1− πn(0, l)]
+
(J +1)× (L+ 1)
Nn(0,0)πn(0,0)[1− πn(0,0)]
]
.
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Furthermore, criterion C4 coincides with C5 and is given by
tr
(
σ2
n
DtM−1D
)
= tr
(
σ2
n
EtM−1E
)
(3.7)
= tr
(
σ2
n
M−1
)
− σ
2
Nn(0,0)πn(0,0)[1− πn(0,0)] .
Proof. See Appendix A.1. 
Remark 3.1. Contrary to C1 and C2, from (3.6) and (3.7) it is easy to
see that the trace criteria C3–C5 treat the covariate profiles in a different
way due to the nature of the OLS estimators and the fact that these crite-
ria correspond to the minimization of the mean variance of the estimators
of the parameters of interest without taking into account their covariance
structure.
Note that C1–C5 depend on the design only through the allocation vec-
tor pi; it is also straightforward to check that the above criteria are strictly
convex in pi and will be minimized by (3.2) independently on the covariates.
However, the loss of inferential precision expressed by C1–C5 is random
since it depends on the number of subjects within the different strata Nn,
that is, ΦI =ΦI(pin,Nn). Therefore, in order to remove the effect due to the
random covariates, from now on we take into account the loss of inferential
precision induced by the design
Φ˜I(pin) =EZ[ΦI(pin,Nn)].(3.8)
4. Optimal design for ethics. From an ethical viewpoint, a natural de-
mand consists in an overall benefit for the entire sample of patients involved
in the trial, for instance maximizing for any given sample size the percent-
age of patients who receive the best treatment. This make sense if and only
if the treatment effects are different; otherwise there is no longer a worse
treatment, stressing that the comparative experiment degenerates to just
one treatment.
Assuming model (2.1), at each stratum (tj ,wl) the superiority/inferiority
of A or B depends only on the sign of θ in (2.2), and from now on we
let for simplicity θ(j, l). Assuming “the-larger-the-better” scenario, for each
subject with covariate profile (tj,wl) the allocation will be made to the supe-
rior treatment if δi1{θ(j,l)>0}+ (1− δi)1{θ(j,l)<0}; otherwise, if θ(j, l) = 0 the
two treatment arms collapse and all the allocations are equivalent (i.e., any
ethical measurement is no longer useful). Thus, the percentage of patients
assigned to the best treatment is
1
n
J∑
j=0
L∑
l=0
Nn(j, l)
{
1
2
−
[
1
2
− πn(j, l)
]
sgn(θ(j, l))
}
,
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where sgn(x) represents the sign of x. However, from (2.2) the relative per-
formance of the treatments depends on the subject’s covariates, so that
a reasonable ethical measure is
ΦE(pin,Nn)
(4.1)
=
1
n
J∑
j=0
L∑
l=0
Nn(j, l)|θ(j, l)|
{
1
2
−
[
1
2
− πn(j, l)
]
sgn(θ(j, l))
}
,
under which every choice is weighed by the relative ethical gain |θ(j, l)|.
Obviously, criterion (4.1) depends on both the covariate profiles and the
unknown parameters of the model and the optimal ethical target, namely
the allocation that assigns all the patients to the better treatment, is
pi∗E = {π∗E(j, l) = 1{θ(j,l)>0} for any j = 0, . . . , J and l= 0, . . . ,L}.(4.2)
Remark 4.1. In the absence of treatment/covariate interactions, θ(j, l) =
α for any j = 0, . . . , J and l= 0, . . . ,L, so that criterion (4.1) simply becomes
ΦE(pin) =
|α|
2
+
(
1
n
n∑
i=1
δi − 1
2
)
α,
that depends on the design only through the total proportion of assignments
to A. Thus, under (2.4) the percentage of allocations to the best treatment
does not depend on the covariates, which are irrelevant from an ethical
viewpoint, so that the optimal ethical target is π∗E(j, l) = 1{α>0} for any (j, l).
Analogously to (3.8), in order to remove the random effect due to covari-
ates from now on we adopt as ethical criterion Φ˜E(pin) = EZ[ΦE(pin,Nn)]
given by
Φ˜E(pin) =
J∑
j=0
L∑
l=0
p(j, l)|θ(j, l)|
{
1
2
−
[
1
2
− πn(j, l)
]
sgn(θ(j, l))
}
.(4.3)
5. The compromise criterion. In order to obtain a suitable compromise
between inferential precision and ethical demands, there are several pos-
sible approaches. Among them, a trade-off the criteria via a combined or
a constrained optimization has, to the best of our knowledge, the strongest
theoretical justification; see, for example, [4, 9–11, 17, 22]. For the sake
of generality, we now suggest a methodology based on the optimization of
a compound criterion that mediates between information and ethics, since
the constrained optimization approach can be regarded as a special case of
this proposal (as it will be shown in Remark 6.1).
Note that, for any chosen inferential criterion C1–C5, Φ˜I and Φ˜E are not
homogeneous measures, and in order to put them in a comparable scale, we
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consider their standardized version, that is,
ΨE(pin) =
Φ˜E(pin)
Φ˜E(pi∗E)
and ΨI(pin) =
Φ˜I(pi
∗
I)
Φ˜I(pin)
,(5.1)
where pi∗I in (3.2) is the optimal inferential target minimizing Φ˜
I and pi∗E
in (4.2) maximizes (4.3) by assigning all subjects to the best treatment, with
Φ˜E(pi
∗
E) =EZ[|θ(z)|] =
∑J
j=0
∑L
l=0 |θ(j, l)|p(j, l).
Clearly, ΨE,ΨI : [0,1]
(J+1)·(L+1) → [0,1] represent standardized measures
of ethical and inferential efficiency, respectively, that will be maximized.
Therefore, by introducing an ethical weight ω, we let, as a compromise cri-
terion,
Ψω(pin) = ω
{
1
ΨE(pin)
}
+ (1− ω)
{
1
ΨI(pin)
}
,(5.2)
which can be seen as the reciprocal of the weighted harmonic mean of ΨE
and ΨI ; see also [4, 11].
The ethical weight ω in the compound criterion can be chosen by the
experimenter, with 0≤ ω < 1 (we assume ω 6= 1 in order to avoid that the
ethical impact completely overcomes the inferential goal). It may be fixed
a priori or could be modeled as a function of the unknown parameters on
the basis of the given real situation. In the latter case ω is allowed to depend
on the true state of nature, since it is reasonable to suppose that the more
the effects of the treatments differ, the more important for the patients are
the chances of receiving the best treatment, whereas in the case of a small
difference, which is more difficult to detect correctly, more emphasis is given
on inferential precision. In particular, under (2.1) the ethical impact depends
on the covariates, and thus, in order to express an overall measure of ethical
risk for the population of interest, from now on we let ω(EZ[|θ(z)|]) :R+ ∪
{0} → [0; 1) to be a a continuous and increasing function with ω(0)→ 0.
In general, the choice of the weight function depends on the given applied
context. For instance, in Phase III trials the experimenters have often some
information gathered from previous stage trials, and more attention is usu-
ally needed for inference, provided that the ethical costs are not prohibitive
(such as deaths of patients). Thus, ω can be chosen to be an S-shaped func-
tion as
ωs(x) = (1 + x
−2)−2(s+1)[2− (1 + x−2)−2] with s≥ 0.(5.3)
Additionally, since in several clinical situations it is reasonable to assume
that the ethical concern is negligible in the case of small difference between
the treatment performances, for example, up to a value ς of the overall risk,
and then increases rapidly, we may assume ω(x) = 0 for x≤ ς , with ω(x)→ 0
for x→ ς+, and ω(x)→ 1 for x→∞. Whereas, an alternative choice for the
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ethical weight is the cdf of a chi-square r.v. χ2(r), where ω decreases as the
degrees of freedom r increases. By fixing small degrees of freedom, the latter
choice allows us to model the ethical impact in order to grow rapidly, even
when the overall ethical risk is moderate.
Theorem 5.1. For every inferential criterion C1–C5, the compound
criterion Ψω(pin) is a strictly convex function of pin, so there exists a unique
target allocation minimizing (5.2) which is the solution of the system of
equations
[Φ˜E(pin)]
2 ∂Φ˜I(pin)
∂πn(j, l)
(5.4)
=
(
ω
1− ω
)
Φ˜E(pi
∗
E)Φ˜I(pi
∗
I)θ(j, l)p(j, l) ∀(j, l).
Proof. The suggested compound criterion is a linear combination of the
reciprocals of ΨI and ΨE . Clearly, [ΨI ]
−1 is strictly convex; moreover Φ˜E
in (4.3) is linear, and thus concave, and it is also non-negative, so that ΨE
is strictly convex in pin. Therefore, criterion (5.2) leads to a unique target
allocation satisfying ∇Ψω(pin) = 0, namely
ωΦ˜E(pi
∗
E)
∂{[Φ˜E(pin)]−1}
∂πn(j, l)
+
1− ω
Φ˜I(pi∗I)
{
∂Φ˜I(pin)
∂πn(j, l)
}
= 0 ∀(j, l),(5.5)
that leads to (5.4) after simple algebra. 
6. The optimal compound target. In this section we describe the proper-
ties of the allocation pi∗ω = {π∗ω(j, l) : j = 0, . . . , J ; l= 0, . . . ,L} that minimizes
the compromise criterion Ψω in (5.2), and we shall refer to it as “optimal
compound target.” In general, pi∗ω depends on the experimental choice of
the inferential criterion Φ˜I and the ethical weight ω, as well as on the true
state of the nature, that is, the unknown parameters and the probability
distribution p= {p(j, l) : j = 0, . . . , J ; l= 0, . . . ,L} of the covariates.
Theorem 6.1. For every chosen inferential criterion C1–C5, at each
stratum (tj ,wl) the optimal compound target π
∗
ω(j, l) satisfies the following
properties:
• π∗ω(j, l) ∈ (0,1) is a continuous function of α, τ and p, that is, π∗ω(j, l) =
π∗ω(j, l;α,τ ,p), and it is increasing in θ(j, l);
• if (α′,τ ′) and (α′′,τ ′′) are parameter values with corresponding ethical
gains θ′(j, l) =−θ′′(j, l), then for any given covariate distribution p,
π∗ω(j, l;α
′,τ ′,p) = 1− π∗ω(j, l;α′′,τ ′′,p),(6.1)
so that the optimal compound target always assigns more than half the
subjects to the better treatment;
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• if θ(j, l)> 0, then π∗ω(j, l) is increasing in p(j, l), whereas when θ(j, l)< 0,
then π∗ω(j, l) is decreasing in p(j, l).
Proof. For any given stratum (tj ,wl), let k(πn(j, l)) = ∂Φ˜I(pin)/
∂πn(j, l). From the convexity of the inferential criterion, the function k(·)
is monotonically increasing with k(1/2) = 0, due to the optimality of the
jointly balanced design in (3.2). Furthermore, the right-hand side of (5.4)
is a continuous function of α, τ and p, due to the properties of ω(·); it
is straightforward to check that, for any given p(j, l), it is also an increas-
ing function of θ(j, l) and is monotone in p(j, l) (increasing when θ(j, l)> 0
and decreasing if θ(j, l) < 0). Since the sign of the left-hand side of (5.4)
depends only on the sign of k(·), if θ(j, l) > 0 (i.e., A is better than B
for this stratum), then the right-hand side of (5.4) is positive and thus
the optimal compound target π∗ω(j, l) > 1/2; otherwise, if θ(j, l) < 0, then
π∗ω(j, l)< 1/2 and θ(j, l) = 0 if and only if π
∗
ω(j, l) = 1/2. Moreover, observe
that limζ→0 k(ζ) = −∞ and limζ→1 k(ζ) = +∞ and thus π∗ω(j, l) 6= {0,1},
since Φ˜E(·) is limited. By taking the derivative of the left-hand side of (5.4)
with respect to πn(j, l) we obtain
∂k(πn(j, l))
∂πn(j, l)
[Φ˜E(pin)]
2 +2Φ˜E(pin)k(πn(j, l))θ(j, l)p(j, l),
where the first term is always positive, due to the convexity of the inferential
criterion. Furthermore, locally around π∗ω(j, l)
k(π∗ω(j, l))θ(j, l)p(j, l) > 0,
since if θ(j, l)> 0, then π∗ω(j, l)> 1/2 and k(π
∗
ω(j, l))> 0 (and, analogously,
when θ(j, l) < 0). Thus, as a function of πn(j, l) the left-hand side of (5.4)
is locally increasing around π∗ω(j, l), so that π
∗
ω(j, l) is a continuous function
of α, τ and p and it is increasing in θ(j, l) and p(j, l), due to the property of
the right-hand side of (5.4). Concerning (6.1), for a given covariate distribu-
tion p the ethical criterion in (4.3) can be regarded as a function of πn(j, l)
and θ(j, l) by letting
J∑
j=0
L∑
l=0
|θ(j, l)|p(j, l)
{
1
2
−
[
1
2
−πn(j, l)
]
sgn(θ(j, l))
}
= υ+ g(πn(j, l), θ(j, l)),
where
g(πn(j, l), θ(j, l)) = |θ(j, l)|p(j, l)
{
1
2
−
[
1
2
− πn(j, l)
]
sgn(θ(j, l))
}
,
so the left-hand side of (5.4) can be rewritten as [υ + g(πn(j, l), θ(j, l))] ·
k(πn(j, l)). First of all note that, for every chosen inferential criterion C1–
C5 the function k(·) is symmetric around the point (1/2; 0) since k(1/2 +
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ǫ) =−k(1/2− ǫ) for any ǫ ∈ (0; 1/2). Moreover, g(1/2 + ǫ, θ(j, l)) = g(1/2−
ǫ,−θ(j, l)), so that the left-hand side of (5.4) is also symmetric around
(1/2; 0), and this implies the symmetric property of the compound target.

6.1. Example: the inferential criteria based on the determinant. From (3.4)
and (3.5) it is easy to see that C1 and C2 have the same standardized version,
ΨI(pin) = 4
(J+1)(L+1)
J∏
j=0
L∏
l=0
πn(j, l)[1− πn(j, l)].(6.2)
Assuming now two binary covariates and two different scenarios for their
population distribution, that is, a uniform one U where each stratum is
equally represented, that is, p(0,0) = p(1,0) = p(0,1) = p(1,1) = 0.25, and
a nonuniform distribution NU with p(0,0) = 0.2, p(1,0) = 0.3, p(0,1) = 0.4,
p(1,1) = 0.1. Table 1 shows the derived optimal compound targets in the
case of four different ethical weights, namely the cdf’s of a χ2(r) with r= 1, 2
and ωs in (5.3) with s= 1,2.
The optimal compound target always assigns the majority of subjects
to the better treatment. The ethical weight increases as r and s decrease,
and therefore less emphasis is given to the inferential precision and more
attention to ethical demands, as expected. Furthermore, since criteria C1
and C2 treat every stratum in the same way, when p(j, l) = p(j˜, l˜) and
θ(j, l) = 1− θ(j˜, l˜), then π∗ω(j, l) = 1− π∗ω(j˜, l˜).
6.2. Example: the inferential criteria based on the trace. Consider two
binary covariates under the same settings of the previous example. By taking
the approximation EZ[Nn(j, l)
−1] = [np(j, l)]−1, Table 2 shows the optimal
compound targets when the inferential criterion C3 is adopted, whereas
Table 3 deals with criterion C4 (or, equivalently, C5).
Note that, since C3–C5 treat the strata in a different way, even if p(0,1)=
p(1,1)=0.25 and θ(0,1)=−θ(1,1)=−1, that is, when (α,τ t)=(−4,−1,3,3),
then π∗ω(0,1) 6=1−π∗ω(1,1).
In general, when r = s the ethical skew is larger if we adopt the cdf
of χ2(r) w.r.t. ωs, and this skew is particularly high for r = 1, which could
induce strong imbalances among the treatment groups (see Tables 1–3 with
(α,τ t) = (−4,−1,3,3)) and, consequently, a great loss of inferential effi-
ciency. This behavior suggests that the adoption of the cdf of χ2(1) is adequate
only in situations with prohibitive ethical costs.
Remark 6.1. Using the analytical expressions of the inferential crite-
ria given in Proposition 3.1, by (5.1) it is also possible to derive optimal
targets via a constrained optimization approach. In the same spirit of [22],
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Table 1
Optimal compound targets adopting criteria C1–C2
(α, τ t) = (1,1,1,1) (α, τ t) = (−4,−1,3,3)
θ(0,0) = 1 θ(1,0) = 2 θ(0,1) = 2 θ(1,1) = 4 θ(0,0) =−4 θ(1,0) =−5 θ(0,1) =−1 θ(1,1) = 1
pi∗ω(0,0) pi
∗
ω(1,0) pi
∗
ω(0,1) pi
∗
ω(1,1) pi
∗
ω(0,0) pi
∗
ω(1,0) pi
∗
ω(0,1) pi
∗
ω(1,1)
χ2(1) NU 0.578 0.700 0.743 0.646 0.278 0.186 0.371 0.534
U 0.593 0.670 0.670 0.771 0.242 0.209 0.415 0.585
χ2(2) NU 0.544 0.623 0.660 0.587 0.352 0.264 0.421 0.520
U 0.554 0.605 0.605 0.689 0.319 0.287 0.449 0.551
ω1 NU 0.537 0.606 0.637 0.572 0.353 0.265 0.421 0.520
U 0.549 0.596 0.596 0.674 0.321 0.289 0.449 0.551
ω2 NU 0.521 0.562 0.581 0.541 0.397 0.324 0.447 0.513
U 0.530 0.559 0.559 0.614 0.373 0.346 0.466 0.534
Table 2
Optimal compound targets adopting criterion C3
(α, τ t) = (1,1,1,1) (α, τ t) = (−4,−1,3,3)
θ(0,0) = 1 θ(1,0) = 2 θ(0,1) = 2 θ(1,1) = 4 θ(0,0) =−4 θ(1,0) =−5 θ(0,1) =−1 θ(1,1) = 1
pi∗ω(0,0) pi
∗
ω(1,0) pi
∗
ω(0,1) pi
∗
ω(1,1) pi
∗
ω(0,0) pi
∗
ω(1,0) pi
∗
ω(0,1) pi
∗
ω(1,1)
χ2(1) NU 0.658 0.868 0.900 0.805 0.179 0.077 0.128 0.677
U 0.697 0.835 0.835 0.916 0.154 0.099 0.214 0.846
χ2(2) NU 0.572 0.792 0.841 0.706 0.277 0.125 0.205 0.582
U 0.598 0.745 0.745 0.866 0.241 0.158 0.318 0.759
ω1 NU 0.557 0.767 0.821 0.678 0.279 0.126 0.206 0.581
U 0.586 0.728 0.728 0.856 0.243 0.159 0.320 0.757
ω2 NU 0.530 0.696 0.760 0.610 0.346 0.169 0.268 0.546
U 0.548 0.658 0.658 0.806 0.308 0.210 0.382 0.692
1
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Table 3
Optimal compound targets adopting criteria C4 or C5
(α, τ t) = (1,1,1,1) (α, τ t) = (−4,−1,3,3)
θ(0,0) = 1 θ(1,0) = 2 θ(0,1) = 2 θ(1,1) = 4 θ(0,0) =−4 θ(1,0) =−5 θ(0,1) =−1 θ(1,1) = 1
pi∗ω(0,0) pi
∗
ω(1,0) pi
∗
ω(0,1) pi
∗
ω(1,1) pi
∗
ω(0,0) pi
∗
ω(1,0) pi
∗
ω(0,1) pi
∗
ω(1,1)
χ2(1) NU 0.677 0.860 0.895 0.795 0.166 0.082 0.137 0.663
U 0.717 0.827 0.827 0.912 0.142 0.105 0.225 0.837
χ2(2) NU 0.585 0.782 0.833 0.694 0.259 0.133 0.217 0.573
U 0.615 0.734 0.734 0.859 0.223 0.167 0.331 0.747
ω1 NU 0.567 0.756 0.812 0.666 0.261 0.134 0.218 0.572
U 0.601 0.717 0.717 0.849 0.225 0.169 0.333 0.744
ω2 NU 0.536 0.685 0.749 0.601 0.328 0.179 0.282 0.541
U 0.558 0.645 0.645 0.797 0.289 0.221 0.393 0.679
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Table 4
Constrained optimal targets adopting criteria C1–C2 and Bandyopadhyay and Biswas’s
allocations piT , with (α,τ
t) = (1,1,1,1) and uniform distribution
θ(0,0) = 1 θ(1,0) = 2 θ(0,1) = 2 θ(1,1) = 4 ΨE ΨI =C
pi∗ωC (0,0) pi
∗
ωC
(1,0) pi∗ωC (0,1) pi
∗
ωC
(1,1)
ωC = 0.356 0.523 0.546 0.546 0.589 0.56 0.95
ωC = 0.483 0.528 0.566 0.566 0.612 0.59 0.9
ωC = 0.700 0.558 0.612 0.612 0.698 0.64 0.75
ωC = 0.883 0.599 0.679 0.679 0.781 0.72 0.5
ωC = 0.969 0.656 0.756 0.756 0.851 0.79 0.25
piT (0,0) piT (1,0) piT (0,1) piT (1,1)
T = 1 0.841 0.977 0.977 0.999 0.97 10−6
T = 2 0.691 0.841 0.841 0.977 0.88 0.02
T = 3 0.631 0.748 0.748 0.909 0.81 0.17
the problem lies in finding the allocation that maximizes the ethical impact
for a chosen inferential efficiency. In our context this corresponds to min-
imize Ψ−1E under the constraint Ψ
−1
I ≤ C−1 for a prefixed constant C < 1
(we exclude the degenerate case C = 1 that corresponds to assume ΨI = 1,
i.e., no ethical concerns), representing a special case of our combined opti-
mization approach; see also [4, 9, 10]. Indeed, due to the strict convexity
of both Ψ−1E and Ψ
−1
I , this is a convex optimization problem, and therefore
the Karush–Kuhn–Tucker (KKT) first order conditions are necessary and
sufficient and guarantee a unique optimal solution pi∗ solving
∇(Ψ−1E (pi∗)) + κ∇(Ψ−1I (pi∗)) = 0,(6.3)
where κ≥ 0 is the KKT multiplier and
κ(Ψ−1I (pi
∗)−C−1) = 0.(6.4)
First, note that (6.3) corresponds to (5.4) with κ= (1−ω)/ω (where clearly
ω 6= 0, since C 6= 1); thus, the candidate solution pi∗ belongs to the class of
compound optimal targets and should satisfy Ψ−1I (pi
∗) = C−1, since κ > 0.
By using the same arguments of the proof of Theorem 6.1, any compound
target pi∗ω solving (5.4) is a continuous and monotone function of ω and, from
the properties of Ψ−1I , for any fixed C < 1 there exists a unique constant
weight ω = ωC such that pi
∗ = pi∗ωC satisfies (6.4).
As a numerical example, consider now the standardized inferential cri-
terion (6.2) in the case of two binary covariates with (α,τ t) = (1,1,1,1)
and uniform distribution U . The upper block of Table 4 shows the derived
constrained optimal targets as C varies, together with the corresponding
ethical weight ωC of our combined optimization approach and the value of
the ethical criterion ΨE . Moreover, the bottom part of the Table gives the
asymptotic allocations of the procedure suggested by Bandyopadhyay and
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Biswas [7] (and further analyzed in [3]), which are given at each stratum
(j, l) by the standard normal cdf evaluated at θ(j, l)/T , for T = 1,2 and 3.
For instance, an inferential efficiency equal to 75% under the constrained
approach corresponds to an ethical weight equal to 70% in the combined
framework; whereas, assuming C = 0.25 means that the role of ethics is al-
most dominant in the combined optimization. Clearly, the arbitrary choice
of the constant C in the constrained setting can be directly translated in the
subjective choice of ω in the combined approach; however, the possibility of
modeling the ethical weight as a function of the unknown parameters allows
us to discriminate among different situations that could be a-priori only
partially known or, more commonly, completely unknown. For instance, if
we set ωC = 0.483, then the 38.8% of subjects within the stratum (1,1) will
receive the worst treatment; whereas, the percentage of allocations to the
worst treatment is only 22.9% or 32,6% if the cdf of χ2(1) or ω1 are assumed
as weight functions, respectively; see Table 1. Moreover, the allocations pro-
posed by Bandyopadhyay and Biswas (2001) are strongly skewed toward the
better treatment, so that the inferential precision collapses. This is particu-
larly true for small values of T , as emphasized in [18], and this behavior is
also confirmed, even if we adopt criteria C3–C5.
7. The reinforced doubly adaptive biased coin design. As shown previ-
ously, the compound target allocation pi∗ω depends in general on the unknown
parameters of the model and, since this function is continuous, covariate-
adjusted response-adaptive procedures may be called for. These designs use
at each step the observed responses, the covariates and the previous assign-
ments, as well as the covariate profile of the current subject, to modify the
allocations as the experiment goes along in order to gradually approach the
desired target.
In this section we introduce the reinforced doubly adaptive biased coin
design. This is a general class of CARA procedures, which admits both
continuous and discontinuous randomization functions, aimed at targeting
any chosen allocation proportion by forcing closeness to the target when
necessary.
Let now pi∗ = {π∗(j, l) : j = 0, . . . , J ; l = 0, . . . ,L} be a desired allocation
such that, at each stratum (tj ,wl), π
∗(j, l) ∈ (0,1) is a continuous function
of the unknown model parameters γ and p. Suppose that patients come to
the trial sequentially and are assigned to either treatment. Starting with m
observations on each treatment, usually assigned by using restricted random-
ization, an initial non-trivial parameter estimation γ̂2m and p̂2m is derived.
Then, at each step n (n > 2m) let γ̂n and p̂n be the estimators of the pa-
rameters based on the first n observations, where we assume them consistent
in case of i.i.d. observations, so that the optimal target will be estimated by
all the data up to that step by p̂i∗n = pi
∗(γ̂n, p̂n). When the (n+1)st patient
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with covariate profile Zn+1 = (tj ,wl) is ready to be randomized, the rein-
forced doubly adaptive biased coin design assigns to him/her treatment A
with probability
ϕ(πn(j, l); π̂
∗
n(j, l); p̂n(j, l)),(7.1)
where the function ϕ(x, y, z) : (0,1)3 → [0,1] satisfies the following properties:
(i) ϕ is decreasing in x and increasing in y, for any z ∈ (0,1);
(ii) ϕ(x,x, z) = x for any z ∈ (0,1);
(iii) ϕ is decreasing in z if x < y, and increasing in z if x > y;
(iv) ϕ(x, y, z) = 1− ϕ(1− x,1− y, z) for any z ∈ (0,1).
Adopting the RDBCD in (7.1), within each stratum the allocation propor-
tion will be forced to the corresponding target, since from conditions (i)–(ii)
when x ≥ y, then ϕ(x, y, z) ≤ y and if x < y, then ϕ(x, y, z) > y for any
z ∈ (0,1). Furthermore, condition (iv) simply guarantees that A and B are
treated symmetrically, whereas (iii) means that the allocation is forced to-
wards optimality increasingly as the representativeness of the strata in the
population decreases. This property is of great importance since the con-
vergence of the allocation proportion depends on the number of subjects
belonging to each stratum, and therefore it is related to the population dis-
tribution of the covariates. This may be particularly critical for small sam-
ples, where some profiles could be strongly under-represented so that, both
from the ethical and inferential viewpoint, the need to force the closeness to
the target could be greater.
Remark 7.1. In general, at each step the allocation probability (7.1)
does not depend only on the estimates of the unknown parameters related
to the stratum where the current subject belongs; in fact, π̂∗n(j, l) could in-
volve the estimation of the entire set of parameters γ and p. For example,
if we adopt the optimal compound target pi∗ω, at each stratum π
∗
ω(j, l) de-
pends on α, τ and p [see, for instance, (5.4)], so that (7.1) depends on the
information gathered up to that step from all the strata.
Observe that we do not assume the continuity of ϕ, and therefore it is
possible to consider discontinuous randomization functions. For instance,
a natural extension of the ERADE proposed by [14] in the presence of co-
variates is
ϕERADE(x;y; z) =
{
1− ρ(1− y), x < y,
y, x= y, ∀z ∈ (0,1),
ρy, x > y
(7.2)
where the constant ρ ∈ [0,1) controls the degree of randomness.
Remark 7.2. The randomization function in (7.1) could also be chosen
in a different way for each stratum (tj ,wl) by letting ϕ = ϕjl, in order to
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discriminate the importance of each of them and the corresponding closeness
to the target. Furthermore, the RDBCD can be naturally extended to the
case of several treatments.
An interesting family of allocation functions belonging to the RDBCD is
ϕ(x;y; z) = F [D(x;y)H(z)F−1(y)]
/(F [D(x;y)H(z)F−1(y)](7.3)
+F [D(1− x; 1− y)H(z)F−1(1− y)]),
where F :R+ → R+ is continuous and strictly increasing, H(z) is decreas-
ing, while D(x;y) : (0; 1)2 →R+ represents a dissimilarity measure between
the actual allocation proportion x and the current estimate of the optimal
target y, and D is assumed to be decreasing in x and increasing in y, with
D(x;x) = 1.
Example 7.1. Letting D(x;y) = 1 for any (x, y) ∈ (0,1)2, then (7.3)
corresponds to the CARA design analyzed by Zhang et al. [23], namely
ϕZ(x;y; z) = y ∀(x, z) ∈ (0,1)2,(7.4)
which represents an analog of the sequential maximum likelihood design in
the presence of covariates. Whereas if we let F (t) = t, D(x;y) = y/x and
H(z) = ν ≥ 0 ∀z ∈ (0,1), we obtain a natural extension in the presence of
covariates of the family of doubly adaptive biased coin designs, that is,
y(y/x)ν
y(y/x)ν + (1− y)[(1− y)/(1− x)]ν ∀z ∈ (0,1).
However, note that the previous allocation function does not correspond
to the covariate-adjusted doubly adaptive biased coin design suggested by
Zhang and Hu in [24], due to the fact that these authors assume at each
step n a dissimilarity measure between the actual allocation proportion
πn(j, l) and the mean (over the steps) of the estimates of the optimal target
n−1
∑n
i=1 π̂
∗
i (j, l), instead of the current estimate of the target π̂
∗
n(j, l) itself.
Example 7.2. If we set F (t) = tk with k > 0, D(x;y) = 1− (x− y) and
H(z) = z−1 ∀z ∈ (0,1), then (7.3) becomes
ϕBAZ1(x;y; z) =
y[1− (x− y)]k/z
y[1− (x− y)]k/z + (1− y)[1− (y− x)]k/z .(7.5)
In order to account for discontinuous allocation functions, let for instance
F (t) = t, H(z) = {(J +1)(L+1)z}−1 and
D(x;y) =
{1 + ε, x < y,
1, x= y,
1− ε, x > y,
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with ε ∈ [0,1). Then (7.3) becomes
ϕBAZ2(x;y; z)
(7.6)
=

y(1 + ε){(J+1)(L+1)z}
−1
y(1 + ε){(J+1)(L+1)z}−1 + (1− y)(1− ε){(J+1)(L+1)z}−1 ,
x < y,
y, x= y,
y(1− ε){(J+1)(L+1)z}−1
y(1− ε){(J+1)(L+1)z}−1 + (1− y)(1 + ε){(J+1)(L+1)z}−1 ,
x > y,
which allows us to force the allocations toward the chosen target increasingly
the more we move away from the uniform distribution, maintaining at the
same time a good degree of randomness.
Remark 7.3. If we assume only an inferential viewpoint by letting
ω = 0, then the optimal target is the jointly balanced allocation in (3.2),
so that the allocation probability (7.1) corresponds to a stratified random-
ization. For instance, letting F (t) = t2, H(z) = 1 and D(x;y = 1/2) = 1−
2(x− 1/2), then procedure (7.3) corresponds to the DA-optimal design pro-
posed by Atkinson [1],
[1− πn(j, l)]2
[1− πn(j, l)]2 + πn(j, l)2 ;
see the supplementary data in [5] for details.
Let pi∗tj⊗W = (π
∗(j,1)p(j,1), . . . , π∗(j,L)p(j,L))t and p˜i∗t = (pi∗t
T
,pi∗t
W
,
pi∗t
T⊗W), where
pi∗T =
(
L∑
l=0
π∗(1, l)p(1, l), . . . ,
L∑
l=0
π∗(J, l)p(J, l)
)t
,
pi∗W =
(
J∑
j=0
π∗(j,1)p(j,1), . . . ,
J∑
j=0
π∗(j,L)p(j,L)
)t
and pi∗
T⊗W given by
(π∗(1,1)p(1,1), . . . , π∗(1,L)p(1,L), . . . ,
π∗(J,1)p(J,1), . . . , π∗(J,L)p(J,L))t.
The following theorem establishes the strong consistency of both the al-
location proportion and the estimator of the target, as well as the strong
consistency and asymptotic normality of the estimators of the unknown pa-
rameters of the model.
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Theorem 7.1. For any given target allocation pi∗ ∈ (0,1)(J+1)·(L+1) which
is a continuous function of the unknown model parameters γ and p, then
adopting the reinforced doubly adaptive biased coin design (7.1), as n tends
to infinity
pin→ pi∗ a.s. and p̂i∗n→ pi∗ a.s.(7.7)
Furthermore,
γˆn→ γ a.s. and
√
n(γˆn − γ)→N(0;M−1(pi∗)) in law,(7.8)
where M(pi∗) is
J∑
j=0
L∑
l=0
π∗(j, l)p(j, l) 0 p˜i∗t 01×p
0 1−
J∑
j=0
L∑
l=0
π∗(j, l)p(j, l) 01×p 1
t
p − p˜i∗t
p˜i∗ 0p×1 M
A 0p×p
0p×1 1p − p˜i∗ 0p×p MB

,
with
M
A =
(
M
A
11 M
A
12
(MA12)
t M
A
22
)
,(7.9)
such that MA22 = diag(pi
∗
T⊗W),
M
A
11 =

pi∗tt1⊗W
diag(pi∗
T
)
...
pi∗ttJ⊗W
pi∗t1⊗W . . . pi
∗
tJ⊗W
diag(pi∗
W
)
 ,
M
A
12 =

pi∗tt1⊗W 0 0 . . . 0
0 pi∗tt2⊗W 0 . . . 0
...
. . . 0
0 0 . . . pi∗ttJ⊗W
diag(pi∗t1⊗W) diag(pi
∗
t2⊗W
) . . . diag(pi∗tJ⊗W)
 .
Moreover, MB is partitioned similarly to (7.9) with treatment A replaced
by B, that is, MB22 = diag(1JL −pi∗T⊗W),
M
B
11
=

1t
L
−pi∗t
t1⊗W
diag(1J −pi∗T)
...
1t
L
−pi∗t
tJ⊗W
1L −pi∗t1⊗W . . . 1L −pi∗tJ⊗W diag(1L −pi∗W)
 ,
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M
B
12
=

1t
L
−pi∗t
t1⊗W
0 0 . . . 0
0 1t
L
−pi∗t
t2⊗W
0 . . . 0
...
. . . 0
0 0 . . . 1t
L
−pi∗t
tJ⊗W
diag(1L −pi∗t1⊗W) diag(1L −pi∗t2⊗W) . . . diag(1L −pi∗tJ⊗W)
.
Proof. See Appendix A.2. 
Note that the asymptotic normality of the allocation proportions can be
derived as in [13, 14, 23] by adding suitable conditions of differentiability for
the target pi∗ and, eventually, for ϕ.
Corollary 7.1. Let the optimal compound target pi∗ω be the desired
allocation, then adopting the RDBCD in (7.1), as n tends to infinity
pin→ pi∗ω a.s. and p̂i∗n→ pi∗ω a.s.
γˆn→ γ a.s. and
√
n(γˆn − γ)→N(0;M−1(pi∗ω)) in law.
8. Finite sample properties. In order to perform some finite sample com-
parisons, we have conducted a simulation study by adopting the inferential
criterion C1 and assuming as ethical weight function ω the cdf of χ2(1). More-
over, we have taken into account normal responses with σ2 = 1 and two bi-
nary covariates with the previously used settings, that is, (i) two population
scenarios, namely the uniform distribution U and the nonuniform one NU
with p(0,0) = 0.2, p(1,0) = 0.3, p(0,1) = 0.4, p(1,1) = 0.1, (ii) two parame-
ter settings: (α,τ t) = (1,1,1,1) and (α,τ t) = (−4,−1,3,3). The results come
from h= 500 simulations with m= 4 and n= 500. Concerning the continu-
ous randomization functions, we consider the CARA design ϕZ in (7.4) and
the RDBCD in (7.5) with k = 1. As regards the discontinuous case, we per-
form the simulations adopting ϕBAZ2 in (7.6) and ϕERADE in (7.2), where
we put ε = ρ = 2/3, for homogeneity. Expectation and standard deviation
(within brackets) of the proportion of allocations to treatment A are given
in Tables 5–8.
In general, ϕZ in (7.4) is characterized by the strongest variability with
respect to the other procedures, since it is based only on the current estimate
of the target, independently on the actual allocation proportion. Moreover,
as theoretically shown in [23], the variability of this design increases as the
representativeness of the strata decreases, and this behavior is also confirmed
by ϕERADE; see Tables 7 and 8. On the other hand, ϕBAZ1 and ϕBAZ2
tend to balance the variability of the allocation proportions between the
different population strata. Indeed, the standard deviations of the design
in the different patterns are similar, since the reinforced doubly adaptive
biased coin design forces the closeness to the desired target the more the
strata are under-represented.
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Table 5
Expectation and standard deviation (within brackets) of the proportion of allocations to A
under the uniform distribution U with (α,τ t) = (1,1,1,1), so that the optimal compound
target is pi∗ω(0,0) = 0.593, pi
∗
ω(1,0) = pi
∗
ω(0,1) = 0.670 and pi
∗
ω(1,1) = 0.771
pin(0,0) pin(1,0) pin(0,1) pin(1,1)
ϕZ 0.592 0.667 0.666 0.764
(0.051) (0.049) (0.045) (0.041)
ϕBAZ1 0.592 0.667 0.670 0.768
(0.027) (0.027) (0.026) (0.025)
ϕBAZ2 0.591 0.668 0.669 0.769
(0.017) (0.016) (0.016) (0.014)
ϕERADE 0.589 0.665 0.666 0.764
(0.019) (0.019) (0.019) (0.018)
Note that, in general, discontinuous randomization functions perform bet-
ter with respect to the continuous ones. This is quite natural since, when
the allocation proportion is around the target—in particular, for sufficiently
large samples, due to the almost sure convergence—the continuous allocation
procedures randomize the assignment with probability close to the target,
while the discontinuous ones tend to force the allocation in the same way at
each step, even asymptotically.
Moreover, our simulation study points to the fact that ϕBAZ2 guaran-
tees always a stable behavior and tends to have better performances w.r.t.
ϕERADE, especially for strongly under-represented strata. For instance, in
the case of a nonuniform covariate distribution, when (tj ,wl) = (1,1) the
standard deviation of the allocation proportions under ϕBAZ2 is almost half
of the ϕERADE’s one (see Tables 7 and 8).
Table 6
Expectation and standard deviation (within brackets) of the proportion of allocations to A
under the uniform distribution U with (α,τ t) = (−4,−1,3,3), so that the optimal
compound target is pi∗ω(0,0) = 0.242, pi
∗
ω(1,0) = 0.209, pi
∗
ω(0,1) = 0.415 and
pi∗ω(1,1) = 0.585
pin(0,0) pin(1,0) pin(0,1) pin(1,1)
ϕZ 0.250 0.217 0.416 0.582
(0.042) (0.041) (0.049) (0.050)
ϕBAZ1 0.244 0.211 0.412 0.585
(0.024) (0.022) (0.024) (0.026)
ϕBAZ2 0.244 0.212 0.415 0.585
(0.013) (0.013) (0.017) (0.016)
ϕERADE 0.251 0.217 0.417 0.584
(0.017) (0.016) (0.018) (0.019)
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Table 7
Expectation and standard deviation (within brackets) of the proportion of allocations to A
under the nonuniform distribution NU with (α,τ t) = (1,1,1,1), so that the optimal
compound target is pi∗ω(0,0) = 0.578, pi
∗
ω(1,0) = 0.700, pi
∗
ω(0,1) = 0.743 and
pi∗ω(1,1) = 0.646
pin(0,0) pin(1,0) pin(0,1) pin(1,1)
ϕZ 0.576 0.696 0.732 0.651
(0.054) (0.041) (0.034) (0.071)
ϕBAZ1 0.577 0.699 0.739 0.646
(0.026) (0.025) (0.024) (0.028)
ϕBAZ2 0.577 0.698 0.740 0.646
(0.017) (0.015) (0.014) (0.017)
ϕERADE 0.576 0.694 0.738 0.640
(0.021) (0.018) (0.014) (0.030)
The same conclusions have been observed through further simulations,
omitted here for brevity, with larger sample size. However, in this paper
we decided to present the case of n = 500 in order to emphasize the evo-
lution of our procedure, with respect to the others, especially for strongly
under-represented strata (note that the expected number of patients within
stratum (1,1) under the nonuniform distribution NU is 50).
9. Discussion. In the context of clinical trials for treatment comparisons,
several different approaches have been proposed in the literature in order to
provide a valid trade-off between ethical concerns and inferential precision
(such as group sequential designs, interim analysis, etc.) and over the past
Table 8
Expectation and standard deviation (within brackets) of the proportion of allocations to A
under the nonuniform distribution NU with (α,τ t) = (−4,−1,3,3), so that the optimal
compound target is pi∗ω(0,0) = 0.279, pi
∗
ω(1,0) = 0.186, pi
∗
ω(0,1) = 0.371 and
pi∗ω(1,1) = 0.534
pin(0,0) pin(1,0) pin(0,1) pin(1,1)
ϕZ 0.284 0.197 0.377 0.539
(0.050) (0.041) (0.035) (0.073)
ϕBAZ1 0.279 0.188 0.373 0.535
(0.026) (0.021) (0.026) (0.024)
ϕBAZ2 0.280 0.189 0.373 0.534
(0.015) (0.015) (0.013) (0.013)
ϕERADE 0.286 0.195 0.375 0.533
(0.019) (0.018) (0.014) (0.023)
24 A. BALDI ANTOGNINI AND M. ZAGORAIOU
20 years there has been a growing stream of statistical papers on the topic
of response-adaptive randomization; see, for instance, the seminal books of
[12, 16]. Within this framework, in this paper we suggest a design strategy
that combines efficiency and ethical gain for responses following a linear ho-
moscedastic model. By using a compound optimization approach we derive
optimal target allocations for the treatments that can be implemented via
the adoption of a new class of CARA randomization procedure. Through
the proposed methodology, the optimal compound allocations move away
from balance (i.e., the optimal inferential target) toward the better treat-
ment adaptively, on the basis of the treatment effects. Since joint balance
implies marginal one, the proposed design strategy is robust with respect to
possible misspecification of the model in terms of presence or absence of in-
teractions among prognostic factors, or between treatments and covariates.
Moreover, the proposed methodology is quite robust and performs well, even
in the case of approximate homoscedasticity of the outcomes (perhaps after
suitable transformations), as also pointed out by [3, 18]. On the other hand,
in the case of heteroscedastic responses and, more generally, for generalized
linear models, balance does not imply efficiency; our approach could still
be applied, but with different inferential criteria (that could be optimized
numerically) and different weight functions. Further research is needed on
this topic.
APPENDIX
A.1. Proof of Proposition 3.1.
C1. For the sake of simplicity in this Appendix, we will often omit the
subscripts indicating the dimensions of vectors and matrices. Let M˜= nM,
then
detM˜= det

n∑
i=1
δi δ
tF 0 01×p
Ftδ Ft∆F 0p×1 0p×p
0 01×p n−
n∑
i=1
δi (1− δ)tF
0p×1 0p×p F
t(1− δ) Ft(I−∆)F

.
Let ΩA =F
t∆F and ΩB =F
t(I−∆)F, and we obtain that
detM˜= detΩA
{
n∑
i=1
δi − δtFΩ−1A Ftδ
}
× detΩB
{(
n−
n∑
i=1
δi
)
− (1− δ)tFΩ−1B Ft(1− δ)
}
.
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Let now δtF = (N˜t
T
, N˜t
W
, N˜t
T⊗W), where N˜
t
T
= (N˜ (t1), . . . , N˜(tJ)), N˜
t
W
=
(N˜ (w1), . . . , N˜(wL)) with N˜(tj) =
∑L
l=0 N˜(j, l) and N˜(wl) =
∑J
j=0 N˜(j, l),
and N˜t
T⊗W = (N˜ (1,1), . . . , N˜(1,L), . . . , N˜(J,1), . . . , N˜(J,L)). Clearly, N˜(tj)
and N˜(wl) are the number of subjects assigned to treatment A within cat-
egory tj of T (j = 0, . . . , J) and wl of W (l = 0, . . . ,L), respectively. Also,
let N˜ttj⊗W = (N˜ (j,1), . . . , N˜(j,L)) and N˜
t
T⊗wl
= (N˜(1, l), . . . , N˜(J, l)). Then,
the matrix ΩA can be partitioned as follows:
ΩA =
(
A B
Bt C
)
,(A.1)
where
A= diag(N˜T, N˜W) +

N˜tt1⊗W
0J×J
...
N˜ttJ⊗W
N˜t1⊗W · · · N˜tJ⊗W 0L×L
 ,
B=

N˜tt1⊗W 0 0 · · · 0
0 N˜tt2⊗W 0 · · · 0
...
. . . 0
0 0 · · · N˜ttJ⊗W
diag(N˜t1⊗W) diag(N˜t2⊗W) · · · diag(N˜tJ⊗W)

and C= diag(N˜T⊗W), where 0K×K is the K-dim zero matrix. Thus,
Ω−1A =
(
0 0
0 C−1
)
+
(
IJ+L
−C−1Bt
)
Γ−1(IJ+L,−BC−1),(A.2)
where Γ =A − BC−1Bt = diag(N˜T⊗w0 , N˜t0⊗W). Note that ΩA is nonsin-
gular if and only if C and Γ are nonsingular and detΩA = detC · detΓ=∏J,L
j,l=1 N˜(j, l)
∏J
j=1 N˜(j,0)
∏L
l=1 N˜(0, l). From (A.2) it follows that
δtFΩ−1A F
tδ = δtF
(
0 0
0 C−1
)
Ftδ+δtF
(
IJ+L
−C−1Bt
)
Γ−1(IJ+L,−BC−1)Ftδ,
where
δtF
(
0 0
0 C−1
)
Ftδ =
J∑
j=1
L∑
l=1
N˜(j, l)
and
δtF
(
IJ+L
−C−1Bt
)
Γ−1(IJ+L,−BC−1)Ftδ =
J∑
j=1
N˜(j,0) +
L∑
l=1
N˜(0, l),
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since
BC−1 =

1tL 0 · · · 0
0 1tL · · · 0
...
. . .
...
0 0 · · · 1tL
IL IL · · · IL
(A.3)
and
Γ−1BC−1
(A.4)
=

N˜(1,0)−11tL 0 · · · 0
0 N˜(2,0)−11tL · · · 0
...
. . .
...
0 · · · N˜(J,0)−11tL
diag(N˜t0⊗W)
−1 diag(N˜t0⊗W)
−1 · · · diag(N˜t0⊗W)−1
 .
Therefore, δtFΩ−1A F
tδ =
∑J
j=1
∑L
l=1 N˜(j, l) +
∑J
j=1 N˜(j,0) +
∑L
l=1 N˜(0, l),
and consequently
∑n
i=1 δi − δtF(ΩA)−1Ftδ = N˜(0,0). Hence,
detM˜=
J∏
j=0
L∏
l=0
N(j, l)2π(j, l)[1− π(j, l)]
and thus (3.4) follows directly.
C2. Note that M˜−1 can be partitioned as follows:
M˜−1 =
(
M˜−111 M˜
−1
12
(M˜−112 )
t M˜−122
)
,
where M˜−111 is given by

n∑
i=1
δi 0
0 n−
n∑
i=1
δi
−
(
δtFΩ−1A F
tδ 0
0 (1− δ)tFΩ−1B Ft(1− δ)
)
−1
=
(
N(0,0)π(0,0) 0
0 N(0,0)[1− π(0,0)]
)−1
,
M˜−112 =−M˜−111
(
δtF 0
0 (1− δ)tF
)(
Ω−1A 0
0 Ω−1B
)
,
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and
M˜−122 =
(
Ω−1A 0
0 Ω−1B
)[
I2p −
(
Ftδ 0
0 Ft(1− δ)
)
M˜−112
]
.
Thus, det(DtM−1D) = detM−122 , which is given by
detΩ−1A det
[
Ip +
FtδδtFΩ−1A
N(0,0)π(0,0)
]
detΩ−1B det
[
Ip +
Ft(1− δ)(1− δ)tFΩ−1B
N(0,0)[1− π(0,0)]
]
.
Applying Sylvester’s determinant theorem, we obtain that
detΩ−1A det
[
Ip +
FtδδtFΩ−1A
N(0,0)π(0,0)
]
= detΩ−1A
(
1 +
δtFΩ−1A F
tδ
N(0,0)π(0,0)
)
=
∑n
i=1 δi∏J
j=0
∏L
l=0N(j, l)π(j, l)
.
Analogously for treatment B, so that (3.5) follows easily after simple algebra.
C3–C4. Clearly tr(n−1DtM−1D) = trM˜−122 , so criterion C3 is given by
σ2 tr
(
Ω−1A +
1
N(0,0)π(0,0)
Ω−1A F
tδδtFΩ−1A
)
(A.5)
+ σ2 tr
(
Ω−1B +
1
N(0,0)[1− π(0,0)]Ω
−1
B F
t(1− δ)(1− δ)tFΩ−1B
)
.
Note that tr(n−1σ2EtM−1E) coincides with (A.5) and thus C4 is equal
to C3. Since
Ω−1A =
(
Γ−1 −Γ−1BC−1
−C−1BtΓ−1 C−1+C−1BtΓ−1BC−1
)
,
we obtain tr(Ω−1A ) = tr(Γ
−1) + tr(C−1) + tr(C−1BtΓ−1BC−1). From (A.3)
and (A.4), it follows that
tr(C−1BtΓ−1BC−1)=
J∑
j=1
L∑
l=1
(
1
N˜(j,0)
+
1
N˜(0, l)
)
=
J∑
j=1
L
N˜(j,0)
+
L∑
l=1
J
N˜(0, l)
,
and thus tr(Ω−1A ) is
J∑
j=1
L∑
l=1
(
1
N˜(0, l)
+
1
N˜(j,0)
)
+
J∑
j=1
L∑
l=1
(
1
N˜(j, l)
)
+
J∑
j=1
L∑
l=1
(
1
N˜(0, l)
+
1
N˜(j,0)
)
.
Moreover, from (A.2), (A.3) and (A.4) we obtain δtFΩ−1A = (1
t
J+L,−1tJ ·L)
and thus Ω−1A F
tδδtFΩ−1A has unitary diagonal elements, so that
tr(Ω−1A F
tδδtFΩ−1A ) = J +L+ J ·L. Analogously for treatment B.
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A.2. Proof of Theorem 7.1. As regards the first statement (7.7), at each
stratum (tj ,wl) we will prove the convergence of both πn(j, l) and π̂
∗
n(j, l) to
the target π∗(j, l); for ease of notation we will often omit the subscript (j, l)
assuming that we are fixing the stratum (tj,wl). Let Fn = σ(Y1, . . . , Yn, δ1, . . . ,
δn,Z1, . . . ,Zn) denote the σ-field representing the history of the trial, with
F0 the trivial σ-field, and Gn = σ(Fn,Zn+1). Moreover, let ∆Mi = [δi −
E(δi|Gi−1)]1{Zi=(tj ,wl)}, then {∆Mi; i ≥ 1} is a sequence of bounded mar-
tingale differences with |∆Mi| ≤ 1 for any i≥ 1; thus the sequence {Mn =∑n
i=1∆Mi;Gn} is a martingale with
∑n
k=1E[(∆Mi)
2|Gk−1]≤Nn.
Let ln =max{s : 2m+ 1≤ s≤ n, N˜s −Nsπ̂∗s ≤ 0}, with max∅= 2m, and
note that
N˜n = N˜ln+1 +
n∑
k=ln+2
∆Mk +
n∑
k=ln+2
E(δk|Gk−1)1{Zk=(tj ,wl)}
≤ N˜ln +1+Mn −Mln+1 +
n∑
k=ln+2
ϕ(πk−1; π̂
∗
k−1; p̂k−1)1{Zk=(tj ,wl)}
< N˜ln +1+Mn −Mln+1 +
n∑
k=ln+2
π̂∗k−11{Zk=(tj ,wl)}
= N˜ln +1+Mn −Mln+1 +
n∑
k=1
π̂∗k−11{Zk=(tj ,wl)} −
ln+1∑
k=1
π̂∗k−11{Zk=(tj ,wl)},
since for any i ≥ ln + 1, ϕ(πi; π̂∗i ; p̂i) < π̂∗i < πi; whereas N˜ln ≤ Nln π̂∗ln and
thus
N˜n −Nnπ̂∗n ≤
(
Nlnπ̂
∗
ln −
ln+1∑
k=1
π̂∗k−11{Zk=(tj ,wl)}
)
+Mn −Mln+1 + 1
−
(
Nnπ̂
∗
n −
n∑
k=1
π̂∗k−11{Zk=(tj ,wl)}
)
.
Since p(j, l) > 0 for each stratum (tj ,wl), then as n→∞, Nn →∞ a.s.
and therefore N−1n Mn→ 0 a.s.; see, for instance, [21]. Furthermore, as n→
∞, p̂n → p a.s. and at least one of the the number of assignments to the
treatments, namely N˜n and (Nn − N˜n), tends to infinity a.s. As showed
in [14], in any case γ̂n has finite limit so that, from the properties of π
∗,
there exists a v ∈ (0,1) such that
π̂∗n→ v a.s.(A.6)
and so
π̂∗n −
∑n
k=1 π̂
∗
k−11{Zk=(tj ,wl)}∑n
k=1 1{Zk=(tj ,wl)}
→ 0 a.s.
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As n→∞, then ln→∞ or supn ln <∞; in either case,
π̂∗ln
Nln
Nn
−
∑ln+1
k=1 π̂
∗
k−11{Zk=(tj ,wl)}∑n
k=1 1{Zk=(tj ,wl)}
→ 0 a.s.
and therefore
(πn − π̂∗n)+→ 0 a.s.(A.7)
Let λn = max{s : 2m+ 1 ≤ s ≤ n, (Ns − N˜s)−Ns(1− π̂∗s) ≤ 0}, for any i≥
λn +1, we have ϕ(πi; π̂
∗
i ; p̂i) = 1−ϕ(1− πi; 1− π̂∗i ; p̂i)> π̂∗i > πi. Then,
Nn − N˜n =Nλn+1 − N˜λn+1 +
n∑
k=λn+2
E((1− δk)|Gk−1)1{Zk=(tj ,wl)}
+
n∑
k=λn+2
[(1− δk)−E((1− δk)|Gk−1)]1{Zk=(tj ,wl)}
≤Nλn +1− N˜λn − (Mn −Mλn+1)
+
n∑
k=λn+2
ϕ(1− πk−1; 1− π̂∗k−1; p̂k−1)1{Zk=(tj ,wl)}
<Nλn +1− N˜λn − (Mn −Mλn+1) +
n∑
k=λn+2
(1− π̂∗k−1)1{Zk=(tj ,wl)}
=Nλn +1− N˜λn − (Mn −Mλn+1) +
n∑
k=1
(1− π̂∗k−1)1{Zk=(tj ,wl)}
−
λn+1∑
k=1
(1− π̂∗k−1)1{Zk=(tj ,wl)}.
Hence,
(Nn − N˜n)−Nn(1− π̂∗n)
≤
{
Nλn(1− π̂∗λn)−
λn+1∑
k=1
(1− π̂∗k−1)1{Zk=(tj ,wl)}
}
+1− (Mn −Mλn+1)−
{
Nn(1− π̂∗n)−
n∑
k=1
(1− π̂∗k−1)1{Zk=(tj ,wl)}
}
,
so that
((1− πn)− (1− π̂∗n))+→ 0 a.s.(A.8)
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From (A.7) and (A.8), as n tends to infinity
πn − π̂∗n→ 0 a.s.
and by (A.6)
lim
n→∞
πn = lim
n→∞
π̂∗n = v a.s.
Since 0< v < 1, then 0< 1− v < 1 and thus
lim
n→∞
N˜n→∞ a.s. and lim
n→∞
(Nn − N˜n)→∞ a.s.
Therefore, limn→∞ γ̂n→ γ a.s. and from the continuity of the target
limn→∞ π̂
∗
n = π
∗ = v a.s., that is,
lim
n→∞
πn = π
∗ a.s.(A.9)
Taking into account the average information matrix M in (2.3), from (A.9)
and the proof of Proposition 3.1 it follows that
lim
n→∞
n−1
n∑
i=1
δi =
J∑
j=0
L∑
l=0
π∗(j, l)p(j, l) a.s.
lim
n→∞
n−1δtF= p˜i∗t a.s. and lim
n→∞
n−1Ft∆F=MA a.s.
Thus, as n goes to infinity the information matrix converges almost surely
to M(pi∗), which is nonsingular since
∑J
j=0
∑L
l=0 π
∗(j, l)p(j, l) ∈ (0,1), MA
and MB are nonsingular, and the matrix
J∑
j=0
L∑
l=0
π∗(j, l)p(j, l) 0
0 1−
J∑
j=0
L∑
l=0
π∗(j, l)p(j, l)

−
(
δtF 0
0 (1− δ)tF
)(
M
A 0
0 MB
)−1(
Ftδ 0
0 Ft(1− δ)
)
=
(
π∗(0,0)p(0,0) 0
0 1− π∗(0,0)p(0,0)
)
is nonsingular too, since π∗(0,0)p(0,0) ∈ (0,1). Thus, the asymptotic nor-
mality of γ̂n follows directly.
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Supplement to “Multi-objective optimal designs in comparative clinical
trials with covariates: the reinforced doubly adaptive biased coin design”
(DOI: 10.1214/12-AOS1007SUPP; .pdf). An online supplementary file con-
tains the extension of inferential criteria C1–C5 to the case of several co-
variates.
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